Healthcare Distribution Alliance – Patients Move Us.
Share Print
HDA Research Foundation

Research Foundation

Publications

Annually, the HDA Research Foundation undertakes research projects to educate and inform pharmaceutical supply chain stakeholders as they work daily to achieve healthcare efficiencies. The publications featured in this section may be downloaded at no additional cost from HDA's Resources webpage.

91st Edition HDA Factbook: The Facts, Figures and Trends in Healthcare

The HDA Factbook provides comprehensive distribution performance metrics that highlight growth and trends in the pharmaceutical industry.

Included is information on distributor demographics, operations, finances, customers and information systems utilization, as well as analysis of healthcare product sales and trends, U.S. market characteristics (prescription use/healthcare expenditures) and a brief overview of the international marketplace. New to the benchmark are additional tables around returns, drug shortages and product identifiers. 

Sponsors: Apotex Corp. and Real Value Rx dba Hospital Pharmaceutical Consulting (Gold); and Ascend Laboratories, LLC, IQVIA, Johnson & Johnson Health Care Systems Inc., Pharmacy Frist and Teva Pharmaceuticals (Bronze)

"Industry Perspectives on the Personalized Medicine Supply Chain"

Personalized medicine is a rapidly evolving and growing field. The shift from one-size-fits-all medicine to a more targeted, individualized approach has broad implications for the healthcare supply chain and its supporting services. 

The whitepaper defines the different types of personalized medicine, while analyzing the unique supply chains and patient/provider services required to support their distribution, and ultimately, administration to patients. Drawing on interviews with U.S. specialty distributors and pharmaceutical manufacturers, this resource includes perspectives on the current and future state of the personalized medicine supply chain, and additional insights through secondary research.

Sponsors: Cardinal Health 3PL Services and Eisai, Inc.

The First 90 Days: US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19 

Developed in collaboration with Deloitte Consulting LLP, this report examines the challenges faced by the industry in the early stages of the pandemic, and evaluates its performance, including handling surges for critical medicines, minimizing supply disruptions, supporting operations while preserving workforce safety and supporting the evolving public health agenda. 

The report also includes four potential future scenarios that could unfold within the next 6 to 12 months as well as recommendations for the industry to build resilience to future disruptions. 

Sponsors: Cardinal Health Inc., CuraScript SD, Novartis Pharmaceuticals Corporation and PAR Pharmaceutical an Endo International Company (Gold); KeySource (Silver); and Ascend Laboratories, LLC, IQVIA and Upsher-Smith Laboratories, LLC (Bronze)  

2020 Understanding Pharmaceutical Distribution

This new, interactive course is made up of 11 modules illustrating the key pharmaceutical supply chain stakeholders and their functions as products move from the manufacturer to the customer.

The course provides users with new information on DSCSA, supply chain resiliency and the returns/recalls process, with content based on The Role of Distributors in the US Health Care Industry, the 90th Edition HDA Factbook and The Role of Reverse Distribution. Designed with training in mind, the course can be used as a whole, or trainers can pick and choose which modules to focus on. In addition to being mobile friendly, this resource includes a search function and a flash card glossary.

Sponsors: Eisai, Inc.; and Teva Pharmaceuticals

2020 Understanding Specialty Pharmaceutical Distribution 

This turnkey PowerPoint presentation for presenters/trainers as well as industry stakeholders examines how the specialty pharmaceutical supply chain operates and discusses the economics of specialty pharmaceutical distribution.

Sponsors: Genentech, A Member of the Roche Group 

Specialty Pharmaceutical Distribution: Facts, Figures and Trends

The Specialty Pharmaceutical Distribution: Facts, Figures and Trends report is a go-to resource for benchmarking data on specialty distribution and insight into the specialty pharmaceutical marketplace.

Sponsors: Genentech, A Member of the Roche Group and Value Drug Company (Gold); Amneal Pharmaceuticals, Associated Pharmacies, Inc. and Takeda Pharmaceuticals America, Inc. (Silver); Pharmacy First and Reliance Wholesale Inc.(Bronze).

2020 Serialization Readiness Survey

Conducted in the spring of 2020, this survey details pharmaceutical distributors and manufacturers’ preparedness to meet the product serialization requirements of the Drug Supply Chain Security Act (DSCSA).

Sponsors: LSPediA  


The Risks and Realities of Commercial Drug Importation

Based on expert interviews, literature reviews and quantitative data modeling, this report analyzes policies for their commercial feasibility, operational costs to the supply chain and overall effects on patient safety. 

Sponsors: Anda, Inc., Novartis Pharmaceuticals Corporation (Platinum); Astellas Pharma US, Inc., Pfizer Inc. (Gold); Genentech, A Member of the Roche Group (Silver)

“The 340B Drug Pricing Program: Evolution and Looking Forward”

Since 1992, the 340B Drug Pricing Program has played a modest, but increasingly important, role in the U.S. healthcare market. This whitepaper provides a brief overview of the program since inception; the impact of the program on various stakeholders; and presents a forward-looking view on the program given recent public reports and discussion, administration actions and potential legislative changes.


"Biosimilars: The State of the U.S. Market"  

This report analyzes the current market for biosimilars in the U.S. through interviews conducted with senior executives from specialty pharmaceutical manufacturing and distribution companies. 

"Benefits and Impact of the DSCSA on Supply Chain Adjacent Areas"

In fall 2019, the Foundation partnered with the Rutgers University Supply Chain Management Graduate Program. A team of four students, under the direction of Professor Anthony Taitt, worked to identify the future impact of DSCSA on key functional groups across industry stakeholders. 

The students interviewed subject matter experts, generated a survey, analyzed the data and developed a whitepaper. The final project was presented to HDA members through a webinar. 

Sponsors: IQVIA

"Change Management: Best Practices in Contract and Chargeback Administration"

In fall 2018, the Foundation partnered with Rutgers University's Supply Chain Management Graduate Program. A team of five students, under the direction of Professor Irene Gerlovin, worked to identify and describe best practices for managing change in contract and chargeback administration due to system conversions and company mergers and acquisitions. The students interviewed subject matter experts, generated a survey, analyzed the data and developed a whitepaper. The final project was presented to HDA members through a webinar

Sponsors: Amneal Pharmaceuticals, IQVIA and WDSrx - Woodfield Distribution, LLC.  

The Role of Reverse Distribution

Through industry knowledge, interviews and survey results, The Role of Reverse Distribution report highlights the complex reverse distribution process and opportunities for future enhancement.

Sponsors: PharmaLink, Inc. (Silver); Guaranteed Returns (Bronze)

The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain

Through interviews, survey work and secondary data, The Role of Distributors in the U.S. Pharmaceuticals Value Chain explores the critical role distributors play to ensure the efficient and effective distribution of specialty medications.

Sponsors: Anda Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. ; H. D. Smith; and Takeda Pharmaceuticals America, Inc.

© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365